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ABSTRACT
Dendritic cells (DCs) initiate adaptive immune responses after their migration to secondary lymphoid
organs. The LXR ligands/oxysterols and the RXR ligand 9-cis Retinoic Acid (9-cis RA) were shown to
dampen DC migration to lymphoid organs through the inhibition of CCR7 expression. We performed
15 transcriptomics of DCs undergoing maturation in the presence of the LXR ligand 22R-Hydroxycholesterol
(22R-HC). The analysis highlighted more than 1500 genes modulated by 22R-HC treatment, including the
triggering receptor expressed on myeloid cells (TREM)-1, which was found markedly up-regulated. We
tested the effect of other nuclear receptor ligands (NRL) and we reported the induction of TREM-1
following RXR, RAR and VDR activation. From a functional point of view, triggering of TREM-1 induced by
20 retinoids increased TNFα and IL-1β release, suggesting an active role of NRL-activated TREM-1+ DCs in
inflammation-driven diseases, including cancer. Consistently with this hypothesis we detected DCs
expressing TREM-1 in pleural effusions and ascites of cancer patients, an observation validated by the
induction of TREM-1, LXR and RAR target genes when monocyte-DCs were activated in the presence of
tumor-conditioned fluids. Finally, we observed a better control of LLC tumor growth in Trem-1−/- bone
25 marrow chimera mice as compared to wild type chimera mice. Future studies will be necessary to shed
light on the mechanism of TREM-1 induction by distinct NRL, and to characterize the role of TREM-1+
DCs in tumor growth.
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Introduction
Q9 Dendritic cells (DCs) are a group of professional antigen
30 presenting cells involved in both innate and adaptive
immunity.1 DCs capture antigens in inflamed tissues and
after migration to the secondary lymphoid organs present
them to naïve T cells eliciting the adaptive immune
response.2 Both cytokines and the local microenvironment
35 contribute to educate DCs to become inflammatory or
regulatory.3 Indeed, under pro-inflammatory conditions DCs
promote an effective immune response, while in a tolerogenic
environment DCs acquire regulatory functions suppressing
T cell activation and proliferation.4
40 Liver X receptors (LXRs) and their ligands, i.e. oxysterols,
are emerging as new players of many inflammatory diseases,
due to their pleiotropic effects.5 The two LXR isoforms share
a similar amino acidic sequence, but differ in tissue distribu-
tion, with LXRα primarily expressed in liver, kidney, intestine,
45 adipose tissue and macrophages, and LXRβ being expressed
ubiquitously.6 Our group has recently demonstrated that
tumor-derived oxysterols promote tumor growth through
LXRα-dependent and -independent mechanisms.7
Triggering receptor expressed on myeloid cells (TREM)
50cluster genes code for a family of proteins (TREM-1, −2, −3),
broadly expressed on the surface of myeloid cells.8 TREM-1 is
a member of the Ig superfamily of immunoreceptors and it is
a strong amplifier of the immune responses.8 TREM-1 is con-
stitutively expressed by neutrophils and monocytes,9 where it is
55up-regulated by LPS exposure and acts synergistically with
receptors for pathogens-associated molecular patterns.10
Indeed, TREM-1 activation induces an amplification of the
immune response with strong increase of TNFα, IL-1β, IL-8
and CCL2 release. In vivo studies, in the context of septic
60shock, have demonstrated that a soluble form of TREM-1
could work as a decoy receptor, thus reducing circulating
inflammatory cytokines and improving mice survival.11
Moreover, recent evidence has linked TREM-1 to several non-
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infectious acute and chronic inflammatory diseases, including
65 inflammatory bowel diseases, rheumatoid arthritis, psoriasis,
atherosclerosis and cancer.12-14 Noteworthy, in non-small cell
lung cancer (NSCLC) patients the expression of TREM-1 by
tumor-associated macrophages and the increase of the soluble
TREM-1 in pleural effusions have been associated with tumor
70 relapse and poor survival.15
Recently, it has been demonstrated that TREM-1 is
induced in dendritic cells undergoing hypoxia.16 TREM-1+
DCs were indeed found in inflamed joints of children affected
by juvenile idiopathic arthritis.16 The identification of TREM-
75 1 ligands remains controversial and represents an important
issue. Different proteins have been proposed as TREM-1
ligands, such as HMGB-1, PGLYRP1, and Hsp-70.17,18
Furthermore, there is consensus on the role played by several
damage-associated molecular patterns as putative TREM-1
80 ligands.18
Here,we report on the identification of TREM-1 as a new target
of different nuclear receptors, i.e. LXRs, RXRs, RARs andVDR. By
transcriptomic studies we show TREM-1 expression on maturing
DCs treatedwith the oxysterol 22R-Hydroxycholesterol (22R-HC)
85 .Moreover, we demonstrate that retinoids (RXR andRAR ligands)
strongly induceTREM-1 expression, which once triggered by anti-
TREM-1 mAb, induces the release of high amounts of the pro-
inflammatory cytokines IL-1β andTNFαbymyeloidDCs.We also
provide evidence thatTREM-1 is expressed on a subset of so-called
90 inflammatory DCs, ex vivo isolated from pleural and peritoneal
fluids of advanced cancer patients. These results pave the way to
the elucidation of this pathway in inflammation and inflamma-
tion-driven diseases.
Results
95 Gene expression profile of LXR ligand-treated dendritic
cells and characterization of 22R-HC immune-related
genes
Human dendritic cells (DCs) were generated from circulating
monocytes obtained from healthy donors in the presence of
100 GM-CSF/IL-4 for 5 days and treated with 22R-
hydroxycholesterol (22R-HC) (5 μM) and LPS (100 ng/ml)
for 24 hours.
The transcriptional profile of LXR ligand-treated DCs was
then assessed by Gene ChipR microarray analysis. Pairwise
105 comparison between datasets from untreated and 22R-HC-
treated samples revealed a differential modulation of many
transcripts. We found 1517 unique genes modulated, 786 upre-
gulated and 731 downregulated genes, considering an absolute
fold change of 1.5 and FDR < 0.05 (Figure 1(a,b), and
110 Supplementary Table 1). Gene ontology Biological process
(BP) enrichment analysis showed that many up-regulated
genes were associated to cardiovascular system development
pathways (Figure 1(c)) while downregulated genes were
enriched in lipid metabolism pathways (Figure 1(d)).
115 Ingenuity® Pathway Analysis (IPA®) revealed a significant mod-
ulation of the following Top canonical pathways: Biosynthesis of
Steroids (p = 1.5E-07); LXR/RXR Activation (p = 2.54E-07);
Role of IL-17F in Allergic Inflammatory Airway Diseases
(p = 2.9E-06); Atherosclerosis Signaling (p = 5.62E-06) and
120TREM1 Signaling (p = 1.61E-04). Among the pathways modu-
lated by the 22R-HC, the TREM-1 signaling pathway displayed
a differential expression between DCs treated with LPS and
DCs treated with LPS plus 22R-HC (p = 1.61E-04). TREM-1 is
expressed by circulating neutrophils, monocytes, tissue
125macrophages9 and by DCs under hypoxic conditions.16 We
investigated the functional regulation of the expression of
TREM-1 in 22R-HC-treated DCs. We evaluated TREM-1
mRNA expression at different time points (6, 16 and 24 h) in
monocyte-derived DCs obtained from different donors and
130treated with 22R-HC alone (immature DCs) or 22R-HC plus
LPS (maturing DCs). Immature DCs, treated with the LXR
agonist alone, showed TREM-1 mRNA induction only at 6
and 16 hours (Figure 2(a–c)), whereas the combination treat-
ment, i.e. 22R-HC + LPS, induced TREM-1 also after 24 hours
135of treatment (Figure 2(a–c)). However, only the combination
treatment resulted in the up regulation of TREM-1 protein on
the surface of DCs (Figure 2(d,e) and data not shown). The
expression of TREM-1 protein was also observed when DCs
were treated with LPS and the synthetic LXR agonist T0901317
140for 24 hours (hereafter referred to as T1317; Figure 2(f)).
TREM-1 is induced by distinct nuclear receptor ligands
1α,25dihydroxyvitamin D3 has been reported to induce the
expression of TREM-1 in U937 cell line, in peripheral blood
monocytes and in synovial macrophages isolated from patients
145affected by rheumatoid arthritis (RA).19 Given that the expression
of someproteins (i.e. CD38 and sPLA2) can be induced bymultiple
nuclear receptor ligands,20 we wondered whether VDR ligands
and other nuclear receptor ligands could induce TREM-1 in DCs.
To assess this hypothesis, we tested the effects of ligands of VDR,
150RAR, RXR, PPARγ and FXR21 on maturing DCs. As shown in
Figure 3(a), 1α,25dihydroxyvitamin D3, and different retinoids
(AtRA and 9-Cis Retinoic Acid), all used at a final concentration
of 1 μM, induced a strong upregulation ofTREM-1mRNA (Figure
3(a)), while PPARγ and FXR ligands did not (data not shown).We
155confirmed the effects of VDR, RXR and RAR ligands also at
protein levels (Figure 3(b–e)). Of note, the combination of 9-cis
RA tested at 100 nM and 22R-HC at 5 μM triggered a stronger
TREM-1 expression, as compared to the individual compounds
(Figure 3(f)), indicating a synergistic effect possibly related to the
160engagement of the heterodimers LXR/RXR. Importantly, we also
detected TREM-1 expression when DCs were activated for
24 hours with the TLR3 ligand poly I:C (20 μg/ml) in the presence
of 9-cis RA (100 nM), given alone, or combined with 22R-HC
(5 μM) (Supplementary Figure 1).
165TREM-1 promoter contains LXR and RAR responsive
elements
To characterize the mechanisms involved in the upregulation of
TREM-1 induced by oxysterols and retinoids we performed in
silico analysis of the TREM-1 promoter and found different
170putative nuclear receptor responsive elements in the untrans-
lated region between −345 and +1 bp (Figure 4(a)). Therefore,
we planned ChIP assay experiments to determine the relative
enrichment of LXR and RAR to the TREM-1 promoter by
taking advantage of the U937 cell line, as very high numbers
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175 of DCs restrained their use in these experiments. The treatment
of PMA-differentiated U937 with T1317 or AtRA induced
TREM-1 mRNA upregulation (Figure 4(b)). These results were
confirmed also at protein level by flow cytometry analysis (data
not shown). ChIP assay with a specific anti-LXRα mAb was
180 carried out on PMA-activated U937 cells treated for 6 hours
with 1 μM of T1317. By qPCR we detected the recruitment of
LXR to the LXR target gene promoter SREBP-1c used as control
(Figure 4(c)), and importantly to a putative TREM-1 promoter
site (Figure 4(d)). Similar experiments using an anti-RAR spe-
185 cific antibody22 showed the relative enrichment of RAR to the
RAR target gene ALDHA1 and TREM-1 promoters in U937
cells treated for 6 hours with 1 μM of AtRA (Supplementary
Figure 2A and B). Altogether, these results identify TREM-1 as
a target gene of LXR and RAR nuclear receptors in U937 cells.
190Since PMA-activated U937 treated with LXR and RAR ligands
expressed TREM-1 similarly to DCs treated with LXR and RAR
ligands, we speculate that TREM-1 may be a target of LXR and
RAR nuclear receptors also in DCs. However, an effort should
be made in near future to definitely prove it.
195Circulating myeloid DCs express TREM-1 following the
treatment with nuclear receptor ligands and release
pro-inflammatory cytokines after TREM-1 triggering
To investigate whether also circulating myeloid DCs could up
regulate TREM-1 expression, we isolated and cultured myeloid
200DCs isolated from healthy donors with LPS and distinct nuclear
Figure 1. Microarray analysis of monocyte-derived DCs activated with LPS in the presence or in the absence of 22R-Hydroxycholesterol. (a-b) Pairwise comparison
between datasets from untreated and 22R-HC-treated samples revealing a differential modulation of 1517 unique genes (in supplementary Table 1). (a) 786 genes
resulted to be upregulated, and (b) 731 downregulated, considering an absolute fold change of 1.5 and FDR H&B < 0.05 (c-d) Gene Ontology Biological Process (BP)
enrichment analysis showing up-regulated (c) and down-modulated (d) pathways.
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receptor ligands. Myeloid DCs treated with LPS in combination
with distinct nuclear receptor ligands expressed TREM-1, such
as monocyte-derived DCs (Figure 5(a)). TREM-1 is an amplifier
of inflammation and it is known to induce the release of pro-
205 inflammatory cytokines, such as TNFα and IL-1β.9 To determine
whether nuclear receptor ligand-induced TREM-1 receptor was
fully functional, myeloid DCs treated with LPS and various
ligands (22R-HC, AtRA, 9-cis RA and 1α,25dihydroxyvitamin
D3) were plated on a plastic surface coated with an agonist
210TREM-1 mAb or control IgG for 24 h. Collected supernatants
were then assayed for TNFα, IL-1β and IL23 by ELISA assays.
We observed a significant increase of TNFα and IL-1β release
when DCs were treated concomitantly with LPS plus AtRA or
9-cisRA and triggered by anti-TREM-1 mAb (Figure 5(b,c)).
215These cytokines were released in similar amounts by DCs treated
with LPS or LPS plus 22R-HC or 1α,25dihydroxyvitamin D3
Figure 2. Kinetics of TREM-1 expression by DCs treated with LXR ligands. (a-c) Analysis of TREM-1 mRNA expression by immature and mature monocyte-derived DCs
treated with 22R-HC for 6 (a), 16 (b) and 24 (c) hours. Results are representative of three experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not
significant (Student’s t test). (d) A representative FACS analysis of TREM-1 expression by untreated, LPS-treated and LPS plus 22R-HC-treated DCs is shown. (e)
Quantification of the flow cytometry analysis as in (d). Each symbol corresponds to one DC donor tested, and the line represents the mean value. ***, P < 0.001; ****,
P < 0.0001 (analysis of variance ANOVA). (f) Quantification of FACS analysis of DCs treated for 24 hours with LPS and the synthetic LXR agonist T0901317 (T1317).
Each symbol corresponds to one DC donor tested, and the line represents the mean value. ***, P < 0.001; ****, P < 0.0001 (analysis of variance ANOVA). In figures
D and E, DCs were treated with LPS and LPS plus 22R-HC for 24 hours.
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Figure 3. Expression of TREM-1 by DCs treated with RXR, RAR or VDR ligands. (a) Analysis of TREM-1 mRNA expression by monocyte-derived DCs treated with LPS plus
22R-HC, or AtRA, or 9-cis RA or 1α,25dihydroxyvitamin D3 for 24 hours. (b) A representative FACS analysis showing TREM-1 expression by DCs treated with LPS, LPS
plus 9-cis RA, or AtRA or 1α,25dihydroxyvitamin D3. (c) Quantification of FACS analysis as in (b). (d) Quantification of FACS analysis as in (b). (e) Quantification of FACS
analysis as in (b). Each symbol corresponds to one DC donor tested, and the line represents the mean value. ****, P < 0.0001 (analysis of variance ANOVA). (f)
Quantification of FACS analysis of DCs treated with LPS, LPS plus 9-cis RA (100 nM), and LPS plus 9-cis RA (100 nM) and 22R-HC (5 μM). Each symbol corresponds to
one DC donor tested, and the line represents the mean value. ***, P < 0.001; ****, P < 0.0001 (analysis of variance ANOVA).
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(Figure 5(b,c)). Moreover, TREM-1 triggering decreased IL-23
production in all the experimental conditions tested, though
statistically significant decrease was obtained only when DCs
220 were treated with LPS alone (Figure 5(d)). These results indicate
that although distinct nuclear receptors induce the up-regulation
of TREM-1 on LPS-treated DCs, only those activated by reti-
noids (9-cis RA and AtRA) enhance the release of pro-
inflammatory cytokines over LPS stimulation. In agreement
225 with these results, we observed an increased Th1 polarization
(IFNγ+ and TNFα+ cells) by intra-cytokine staining when allo-
geneic naïve CD4+ T cells were stimulated for 6 days with DCs
treated with 9-cis RA and triggered by anti-TREM-1 mAb
(Figure 5(e,f)). We also performed experiments to evaluate
230 whether DCs activated by anti-TREM-1 mAb and supernatants
from these DCs were able to regulate T cell proliferation and
T cell migration, respectively (Supplementary Figure 3A and B).
Monocyte-derived DCs were treated with 9-cis RA and triggered
by anti-TREM-1 mAb or control IgG. Twenty-four hours later,
235 supernatants were collected to perform migration assays,
whereas DCs were used to stimulate CFSE-labelled allogeneic
T cells isolated from healthy donors. FACS analysis performed
6 days after the co-culture did not show any difference between
the two conditions in terms of T cell proliferation
240 (Supplementary Figure 3A). Moreover, conditioned supernatants
were equally effective to induce migration of T cells isolated
from healthy donors (Supplementary Figure 3B).
Inflammatory DCs isolated from neoplastic fluids express
TREM-1
245TREM-1 is involved in the pathogenesis of many inflamma-
tory diseases, such as inflammatory bowel diseases, rheuma-
toid arthritis and cancer.12-14 Based on this, we investigated
the relationship between nuclear receptor ligands and TREM-
1 up-regulation in pathologic conditions where inflammation
250plays a role. Soluble TREM-1 molecules and tumor-associated
macrophages expressing TREM-1 have been associated to
poor prognosis in lung cancer patients.15 We thus wondered
whether DCs present in pleural effusions and ascites from
patients affected by tumors of different histology and ovarian
255cancer, respectively, expressed TREM-1 receptors. In particu-
lar, we asked whether TREM-1 was expressed by monocyte-
derived inflammatory DCs recently characterized in tumor
and inflammatory-associated diseases.23 This population is
characterized by the expression of HLA-DR and CD11c mar-
260kers and turns out to be CD1c+ and CD16− (i.e. CD11b+HLA-
DR+CD11c+CD1c+ and CD16−).23 We sorted the CD11b+
mononuclear cells from pleural effusions and ascites, and
found that the inflammatory DCs were about 6–10% among
the CD11c+HLA-DR+ cells (Figure 6(a,b)). We detected
265a variable percentage of CD1c+CD16−TREM-1+ DCs in fluids
of cancer patients (Figure 6(a,b) and Table 1). This subset was
absent or significantly low in the blood of healthy donors
(Figure 6(a,c) and Table 2). TREM-1 was also expressed by
Figure 4. Chromatin Immunoprecipation assays. (a) In silico analysis of the TREM-1 promoter showing different putative LXRE and RARE responsive elements in the
untranslated region between −345 and +1 bp. (b) qPCR experiments showing TREM-1 mRNA expression by U937 differentiated with PMA for 72h and then treated
with T1317 or AtRA. Results are representative of three experiments. *, P = 0.021; ***, P < 0.001 (analysis of variance ANOVA). (c-d) The selective fold enrichments of
the LXRE responsive elements in the SREBP-1c promoter used as control (c) and in the putative TREM-1 promoter site (d), are shown. U937 cells were treated as
described in (b). UT: Untreated. Results are representative of two experiments. *, P = 0.012; **, P = 0.0074 (Student’s t test).
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CD1c+CD16+ cells both in the blood of healthy donors and
270 tumor fluids (Figure 6(a,b); histograms).
To evaluate the presence of oxysterols and/or retinoids in
pleural effusions we incubated pleural effusions from patients
with tumors of different histology (Supplementary Table 2)
with in vitro differentiated monocyte-derived DCs and mea-
275 sured the induction of LXR (ABCA1) and RAR (TGM2) target
genes as well as the up regulation of TREM-1. Eighteen out of
19 pleural effusions induced the expression of ABCA1, TGM2
as well as TREM-1 in monocyte-derived DCs (Supplementary
Figure 4A, B and C). Moreover, the expression of TREM-1
280 positively correlated with the induction of LXR and RAR
target genes in linear regression analyses (Figure 6(d) and E;
R2 = 0.44 and p-value = 0.004 for ABCA1 vs TREM-1;
R2 = 0.23 and p-value = 0.050 for TGM2 vs TREM-1).
By interrogating the PROGgeneV2 prognostic database, we
285 evaluated whether the expression of TREM1 alone or combined
to ITGAX (CD11c) impacted on overall survival or relapse free
survival24 of NSCLC and ovarian cancer patients. We observed
only a trend between high expressors and reduced overall survival
in both tumors (data not shown). Instead, a significant reduced
290 RFS correlated with tumors with a high expression of TREM1
alone or combined to ITGAX (Supplementary Figure 5A, B, C and
D). Therefore, suggesting a worst prognosis of tumors infiltrated
by high levels of TREM1+ and CD11c+ cells.
TREM-1+ hematopoietic-derived immune cells favor
295 experimental lung tumor progression
To establish the role of TREM-1+ immune cells in tumor
progression, we generatedwild type andTrem-1,3−/- bonemarrow
chimera mice. Two months after bone marrow transplants, chi-
mera mice were challenged with the mouse lung carcinoma LLC,
300 which we have previously shown to release oxysterols.25,26 We
observed a delayed LLC tumor growth in Trem-1,3−/- bone mar-
row chimera mice (Figure 7(a)). We also observed a reduced
number of CD11b+Ly6G+ neutrophils in tumors collected from
Trem-1,3−/- as compared to wild type bone marrow chimera mice
305 (Figure 7(b)). The number of CD11b+CD11c+ cells was instead
similar in tumors collected from both mice (wild type and Trem-
1,3−/- bone marrow chimera) (data not shown), whereas, as
expected, we detected only a few TREM-1+ cells among the
CD45+ cells infiltrating the tumors grown in Trem-1,3−/- bone
310 marrow chimera mice (data not shown), possibly due to residual
wild type bone marrow precursors. Additionally, by immunohis-
tochemistry we detected a higher number of CD3+ and CD8+
T lymphocytes in LLC tumors grown in Trem-1,3−/- bonemarrow
chimera mice (Figure 7(c–e)). It has been recently reported that
315 mice lacking TGFβR1-mediated signaling have a defect in
CD103+CD11b+TREM-1+ DCs in the intestine, which hampers
the generation of antigen-specific inducible FoxP3+ regulatory
T cells.27 In our experiments the absence of TREM-1+ DCs
might explain the increase of CD3+ and CD8+ T lymphocytes in
320LLC tumors grown in Trem-1,3−/- bone marrow chimera mice
(Figure 7(c–e)), possibly related to the reduction of FoxP3+ reg-
ulatory T cells. This hypothesis needs to be carefully evaluated in
appropriate models.
These results suggest that the expression of TREM-1 by tumor
325infiltrating immune cells favors tumor growth and are in accor-
dance with clinical data showing TREM-1+ DCs in pleural fluids
and ascites of cancer patients with advanced disease and bad
prognosis (Figure 7 and Supplementary Table 2).
Discussion
330Here, we characterized the transcriptional profile of mono-
cyte-derived DCs treated with the oxysterol 22R-HC and LPS.
Besides the expected down-modulation of inflammatory
response genes, we also detected the induction of TREM-1,
which is a strong amplifier of immune responses.
335TREM-1 is expressed by monocytes, neutrophils and tissue
macrophages, where it is upregulated by Toll-like receptor ligands
and pro-inflammatory cytokines.9 Its expression is relevant for the
amplification of the immune responses during infections.9 Indeed,
TREM-1 triggering increases the release of TNFα, IL-1β, IL-6, IL-8
340and CCL2, thus fueling the inflammatory circuitry leading to the
clearance of pathogens.11 It is also known that TREM-1 is down-
regulated during DC differentiation from monocytes.9 Until now
only hypoxia has been reported to up-regulateTREM-1 expression
in monocyte-derived DCs, an observation confirmed by the ana-
345lysis of DCs present in synovial fluids of patients affected by
juvenile idiopathic arthritis.16 Here, we demonstrated that the
engagement of different nuclear receptors induced the expression
of TREM-1 onmaturingDCs. LXR/oxysterols, RAR/RXR/retinoic
acids andVDR/1α,25dihydroxyvitaminD3
21 induced a strong up-
350regulation of TREM-1 both at mRNA and protein levels. Of note,
neutrophils and monocytes failed to further up-regulate TREM-1
upon nuclear receptor engagement (data not shown).
Furthermore, the combination of the RXR ligand 9-Cis Retinoic
Acid and 22R-HCgreatly enhancedTREM-1 expression, probably
355due to an additive effect induced by the triggering of the obliged
heterodimer LXR/RXR. We also demonstrated that TREM-1 was
fully functional, as its triggering induced the release of TNFα and
IL-1β. Of note, this effect was observed only when DCs were
treated with LPS and retinoids (9-cis RA and AtRA), but not
360when activated in the presence of 22R-HC or
1α,25dihydroxyvitamin D3. In agreement with these results we
observed a strong Th1 polarization of DCs when TREM-1
Figure 5. Expression and function of TREM-on myeloid DCs isolated from the blood of donors. (a) Quantification by FACS of TREM-1 expression by myeloid DCs treated
with LPS, LPS plus 22R-HC, LPS plus AtRA, LPS plus 9-cis RA, and LPS plus 1α,25dihydroxyvitamin D3. Results are representative of three experiments. *, P < 0.05; **,
P < 0.01; ns, not significant (analysis of variance ANOVA). (b-c) TNFα (b) and IL-1β (c) release by myeloid DCs treated with LPS plus nuclear receptor ligands as
described in (a) and triggered for 24h by anti-TREM-1 mAb or IgG ctrl. Results are representative of 3–4 experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (analysis
of variance ANOVA). (d) IL-23 release by myeloid DCs treated with LPS plus nuclear receptor ligands as described in (a) and triggered for 24h by anti-TREM-1 mAb or
IgG ctrl. Results are representative of 2 experiments. *, P < 0.05 (analysis of variance ANOVA). (e) FACS analysis showing TNFα+ and IFNγ+ cytokine staining of
allogeneic naïve CD4+ T cells stimulated for 6 days with DCs treated with 9-cis RA and triggered by anti-TREM-1 mAb or IgG ctrl. (f) Fold change of TNFα+/IFNγ+ CD4+
T cells co-cultured with DCs stimulated with LPS plus 9-cis RA over TNFα+/IFNγ+ CD4+ T cells co-cultured with DCs stimulated with LPS alone. Results are
representative of 2 experiments. *, P < 0.05; **, P < 0.01; ns, not significant (analysis of variance ANOVA).
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expression was driven by retinoids. These results suggest distinct
functions exerted by different nuclear receptor ligands,whichneed
365 to be investigated in appropriate microenvironmental conditions.
Interestingly, the expression of TREM-1 was up-regulated only
following the simultaneous addition of LPS and nuclear receptor
ligands (i.e. 22R-HC, AtRA, etc.), with the single treatments lead-
ing to a slight or no expression, respectively. This suggests that LPS
370 might induce epigenetic changes favoring the subsequent activity
of the nuclear receptor ligands on the TREM-1 expression.28
We evaluated whether TREM-1-expressing DCs were present
in vivo. To do that we took advantage of pleural and peritoneal
fluids from patients affected by advanced cancers, a condition
375 frequently associated to inflammatory responses, or from patients
affected by heart failure (PE23), a condition sometimes associated
with the formation of pleural effusions containing pro-
inflammatory mediators. Based upon results reporting the identi-
fication of a subset ofmonocyte-derivedDCs in inflamed tissues,23
380 we detected a DC subset expressing TREM-1 in most fluids
analyzed, independently of their malignant or benign nature.
These fluids also induced the expression of TREM-1, as well as
of the LXR and RAR targets when added to differentiating mono-
cyte-derived DCs; thus, functionally demonstrating the presence
385 of oxysterols and retinoids within the fluids.
The regulation of TREM-1 expression induced by nuclear
receptor ligands as well as the presence of TREM-1-expressing
DCs in conditions associated with inflammation, suggest the
involvement of this pathway in physio-pathological conditions,
390 in which an amplification of inflammation is required. In vivo
studies are therefore required to mechanistically explain the rele-
vance of this pathway, and to indicatewhether themanipulation of
this pathway could be useful from a therapeutic standpoint.
In cancer, the increase of s-TREM-1 correlates with poor
395 prognosis in lung cancer patients.15 Moreover, the expression
of TREM-1 in Kupffer cells associates with liver cancer29,30 as
well as colon cancer.31,32 The deletion of the murine homolog
TREM-1 in mice attenuates hepatocellular carcinogenesis trig-
gered by diethylnitrosamine.29 These results are in accordance
400 with our in vivo experiments showing a detrimental effect of
TREM-1+ immune cells infiltrating the LLC tumor model.
Therefore, the detection of TREM-1+ DCs in effusions from
advanced cancer patients seems to be associated with the
aggressiveness of the disease and bad prognosis. Although
405 the latter observation seems to be in sharp contrast with the
induction of Th1 immune response following TREM-1+ DC
engagement, an intriguing hypothesis would reconcile these
two conditions through a possible cross-talk between inflam-
mation and cancer with the former exacerbating the tumori-
410 genic process.33 A careful analysis of tumor
microenvironment at different tumor stages is needed to
clearly define the role of TREM-1+ immune cells during
tumor formation and progression.
It is well known that AtRA and 1α,25dihydroxyvitamin D3
415exert tolerogenic effect on dendritic cells.34-37 In particular,
1α,25dihydroxyvitamin D3 inhibits the differentiation,
maturation and the immunostimulatory capacity of DCs in
a VDR-dependent manner.36,37 Whether, the lack of function-
ality observed upon TREM-1 triggering is responsible for
420tolerogenic effects and whether it is associated to a decoy
function, deserves appropriate experimental settings. AtRA
released by DCs together with TGFβ participate in the differ-
entiation of inducible Treg (iTreg) in the gut mucosa,34,38
a differentiation pathway involved in the induction of oral
425tolerance.39 Interestingly, intestinal macrophages are refrac-
tory to TREM-1 induction by TNF, due to the local presence
of TGFβ and IL-10.40 These two cytokines down-regulate
TREM-1 expression contributing to generate a tolerogenic
environment.40 Nevertheless, in inflammatory conditions
430associated to Toxoplasma gondii infection and to vaccination
with an E. coli-derived heat-labile enterotoxin mucosal adju-
vant, the induction of Th1 and Th17 cell responses are sub-
stantially impaired in vitamin A-deficient mice.41 These
findings demonstrate an essential role of RA in the develop-
435ment of Th1 and Th17 cells.41 The identification of TREM-1
as a target gene of RA could contribute to clarify the mechan-
ism by which RA during pathological conditions exert pro-
inflammatory functions. Although the triggering of TREM-1
induced by the oxysterol 22R-HC does not enhance the
440release of TNFα and IL-1β over LPS, the expression of
TREM-1 by 22R-HC seems to be in sharp contrast with the
anti-inflammatory program exerted by LXRs.42 Indeed, LXRs
reduce the inflammation by antagonizing pro-inflammatory
transcription factors, such as NF-κB,43 by activating genes
445with anti-inflammatory activities, such as Mer and
Abca144,45 and by inducing the synthesis of anti-
inflammatory fatty acids activating SREBP-1.46 Nevertheless,
new protective effects exerted by LXRs are emerging.20
Indeed, LXR activation in macrophages induces the expres-
450sion of CD38, ultimately constraining Salmonella
Typhimurium infection.20 Altogether, these results suggest
specific functions for each nuclear receptor in different con-
texts, an observation that needs further investigations consid-
ering the local generation of the ligands and the relative
455expression of nuclear receptors.
Materials and methods
Reagents, antibodies and cell lines
22R-Hydroxycholesterol, T0901317, All-Trans Retinoic Acids
(AtRA), 9-Cis Retinoic Acid (9-cis RA) and
4601α,25dihydroxyvitamin D3 (Avanti Polar and Sigma-Aldrich)
were used at the concentration of 5 μM and 1 μM. Human
Figure 6. Expression of TREM-1 by DCs isolated from neoplastic fluids of advanced cancer patients. (a-b) Analysis of TREM-1 expression by CD11b+ cells purified from
neoplastic fluids (a, pleural effusion; b, ascites) and further analyzed by FACS for HLA-DR, CD11c, CD1c, CD16 and TREM-1. TREM-1 was expressed by a subset of
CD1c+CD16+ cells present in neoplastic fluids and blood of healthy donors (a, upper panel), and by HLA-DR+CD11c+CD1c+CD16− DCs, which were almost exclusively
present in neoplastic fluids. (c) Whisker plot analysis showing the percentage of HLA-DR+CD11c+CD1c+CD16− DCs expressing TREM-1 in the fluids of 9 advanced
cancer patients and in the blood of 9 healthy donors. *, P = 0.013 (Wilcoxon matched-pairs signed rank test). (d-e) Linear regression analyses between TREM-1
expression and ABCA1 (d) or TGM-2 expression (e).
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DCs were stained with APC anti-TREM-1 (Biolegend), FITC
anti-CD83, APC anti-CD1a (Biolegend) or PE anti-CD1a (BD
Biosciences), FITC or APC-Cy7 anti-CD16 (Biolegend, clone
465 3G8), FITC or APC-Cy7 anti-HLA-DR (BD Biosciences,
Biolegend), Pe-Cy7 anti-CD11c (Biolegend), PE anti-CD11c
(BD Biosciences) or APC anti-CD1c (Biolegend), PE anti-CD
11b (BD Biosciences), APC anti-CD206 (Biolegend), or iso-
type-matched control antibodies. Anti-TREM-1 (R&D
470 Systems, clone 193015). Additionally, we used anti-TREM-1
mAb provided by Marco Colonna. Cells were run on
a FACSCanto (BD Biosciences), and data were analyzed by
FlowJo. U937 cell line was cultured in RPMI 1640 supple-
mented with 10% heat-inactivated fetal calf serum (HyClone).
475 U937 (5 x 105) were differentiated with PMA (Sigma-Aldrich)
10 ng/ml for 72 h. Then, cells were collected, washed and
stimulated with T1317 or AtRA for 6 or 16 hours. LLC cell
line was cultured with RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum (HyClone).
480 Gene expression profiles of DCs
For each sample, RNA samples was prepared and hybri-
dized onto the GeneChip® Gene 1.0 ST Array (Affymetrix,
Santa Clara, CA, USA). The GeneChip® Human Gene 1.0
ST Array (Affymetrix, Santa Clara, CA, USA), which
485 measures gene expression levels of 19,973 well-annotated
genes, using a single probe set per gene comprised of
multiple probes distributed along the entire length of
the genomic locus, thus offering a whole-transcript cover-
age. The array contains 764,885 distinct probes, with
490a mean of 28 probes per gene, and all probe sets are
perfect match (PM) only. Gene 1.0 ST Array probe design
is based on the March 2006 human genome sequence
assembly (UCSC hg18, NCBI Build 36). This platform
provides more than 99% coverage of sequences present
495in the RefSeq database (November, 2006; http://www.ncbi.
nlm.nih.gov/RefSeq/). Starting from 100 ng of total RNA
per sample, biotin labelled targets (cRNA) were prepared
using Ambion® Whole Transcript (WT) Expression Kit
(Applied Biosystems, Life Technologies) and GeneChip®
500WT Terminal Labeling and Controls Kit (Affymetrix),
following manufacturers’ instructions. After fragmenta-
tion, cRNA samples were hybridized on the GeneChip®
Gene 1.0 ST (Affymetrix) at 45° C for 16 hours.
Following hybridization, non-specifically bound material
505was removed by washing and detection of specifically
bound target was performed using the GeneChip®
Hybridization, Wash and Stain kit, and the GeneChip®
Fluidics Station 450 (Affymetrix). The arrays were
scanned using the GeneChip® Scanner 3000 7G
510(Affymetrix) and raw data was extracted from the
scanned images and analyzed with the Affymetrix Power
Tools software package (Affymetrix). Data (CEL files)
discussed in this publication have been deposited in
ArrayExpress repository (http://www.ebi.ac.uk/arrayex
515press/) and are available through the accession number
E-MTAB-6224.
Statistical and bioinformatics analysis of microarray data
Using Partek GS (Partek Genomic Suite, St Louis, MO) we
applied robust microarray analysis method (RMA) to obtain
520normalized intensity expression data of Human Gene 1.0 ST
Array probe sets of 18 samples. Then, to identify statistical
significant differentially modulated genes, we carried out an
ANOVA analysis contrasting two group of samples (9 samples
of LPS treated DCs vs 9 samples of LPS plus 22R-HC treated
525DCs) on the basis of an absolute 1.5 fold-change (FC) cut off,
a significance level of p-value < 0.01 and after Benjamini
Hochberg corrected False Detection Rate (FDR H&B) <0.05.
Functional annotation and gene set enrichment analyses of
differentially expressed genes were carried out by ToppGene
530suite (https://toppgene.cchmc.org/)47 using FDR H&B of 0.05
and gene number range from 10 to 1500. Pathways analysis of
DEG was performed by using Ingenuity® Pathway Analysis
(IPA®, release date: 2012–05-07).
Monocyte-derived DCs
535Human DCs were generated and cultured as described
elsewhere.48 Human iDC at day 5 of culture were harvested
and activated (8 x105 cells) with LPS (100 ng/mL) in 6 wells
plate, in the presence or in the absence of natural/synthetic
LXR, RXR, RAR or VDR agonists. In some experiments, we
540activated DCs with poly I:C (20 μg/ml) in the presence or in
the absence of nuclear receptor ligands.
Table 1. Percentage of TREM-1+ DCs in fluids from cancer patients.
Pleural or peritoneal fluid
samples Tumor histology
% TREM-1+
DR+CD11c+CD1c+CD16−
DCs
#1 (pleural fluid from
lung cancer)
Lung adenocarcinoma 62.9
#2 (ascites from epithelial
ovarian cancer)
Endometrioid type 5.8
#3 (ascites from epithelial
ovarian cancer)
Serous type 6.6
#4 (ascites from epithelial
ovarian cancer)
Papillary serous type 5.5
#5 (ascites from epithelial
ovarian cancer)
Serous type 14.8
#6 (ascites from epithelial
ovarian cancer)
Serous type 4.5
#7 (ascites from epithelial
ovarian cancer)
Serous type 2
#8 (ascites from epithelial
ovarian cancer)
Serous endometrioid
type
3.9
#9 (ascites from epithelial
ovarian cancer)
Malignant
Mixed Müllerian
Tumor type
12.1
Table 2. Percentage of TREM-1+ DCs in the blood of healthy donors.
Healthy donors % TREM-1+ DR+CD11c+CD1c+CD16− DCs
#1 0.0
#2 0.0
#3 0.55
#4 2.97
#5 1.36
#6 1.23
#7 0.26
#8 8.07
#9 0.87
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Isolation of myeloid DCs
Human myeloid DCs were isolated using the Blood Dendritic
Cell Isolation Kit (Miltenyi Biotec). Once isolated, myeloid
545 DCs were activated for 24 h with LPS (100 ng/mL) in the
presence or absence of natural/synthetic LXR, RXR, RAR or
VDR agonists. For MLR experiments, nuclear receptor-treated
DCs were cross-linked by anti-TREM-1 mAb or with the
control and then used to stimulate naïve CD4+ T-cells.
550 Peripheral blood mononuclear cells were obtained by healthy
donors by following the principles of the Declaration of
Helsinki.
TREM-1 cross-linking and ELISA assays
Forty-eight wells plate was coated with 10 μg/ml of agonist
555 anti-TREM-1 mAb (R&D Systems, clone 193015) or with
control IgG1 and incubated overnight at 4°C. After that,
1.5 × 105 DCs/well were plated in RPMI 1640 with cytokines
and in the presence or absence of LXR, RXR, RAR and VDR
ligands. After 24 h the supernatants were harvested and tested
560by ELISA assays to determine cytokine release. TNFα, IL-1β
and IL-23 production by DCs treated with Nuclear Receptor
ligands was assessed with ELISA assays accordingly to the
manufacturer’s recommendations (BD Biosciences
Pharmingen, San Jose, CA).
565Total RNA extraction and purification
Twenty-four hours after seeding, DCs were treated with LPS and
LPS plus 22R-HC at the concentration of 5 μM for 24 hours, with
controls running parallel. Nine replicate samples were carried out
for each condition for a total of 18 samples and total RNA was
570extracted using the Qiazol reagent (Qiagen, Valencia, CA, USA),
and purified using themiRNeasy total RNA Isolation Kit (Qiagen,
Valencia, CA, USA). Quality and quantity of the total RNA
Figure 7. LLC tumor growth in wild type (WT) and Trem-1,3−/- bone marrow chimera mice. (a) Growth of LLC in WT and Trem-1,3−/- chimera mice (n = 12–14 mice per
group; mean ± SEM). **, P = 0.0073; *, P = 0.022 (Student’s t test). (b) Number of CD11b+Ly6G+ neutrophils infiltrating LLC injected in WT or in Trem-1,3−/- chimera
mice (n = 5 mice per group; mean ± SEM). *, P = 0.04 (Student’s t test). (c) Immunohistochemistry for CD3+ cells infiltrating LLC tumors grown in WT (left) and Trem-
1,3−/- (right) chimera mice. Original magnification 200x; bar, 100 μm. (d) Immunohistochemistry for CD8+ cells infiltrating LLC tumors grown in WT (left) and Trem-
1,3−/- (right) chimera mice. Original magnification 400x; bar, 100 μm. (e) Quantification of the results shown in C and D. The amount of immunoreactive CD3+ and
CD8+ cells was calculated as the number of positive cells in tumor areas at 400x magnification in 16 high-power fields enriched of T lymphocytes. *, P < 0.05; ***,
P < 0.001 (analysis of variance ANOVA).
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samples were evaluated with 2100 Bioanalyzer (Agilent, Santa
Clara, CA) and Nanodrop 1000 (Thermo Fisher Scientific,
575 Wilmington, DE), respectively.
Real-time RT-PCR
Total RNA was isolated with TRIZOL reagent (Invitrogen).
Reverse transcription was performed from 1–2 μg of total
RNA, incubating 1 hour at 42°C with MLV-reverse transcrip-
580 tase (Invitrogen). Quantitative PCR was performed using real-
time PCR (ViiA7, Applied Biosystems), 40 cycles of 95°C for
12 s and 60°C for 1 min using SybrGreen. Primers used are
shown in Supplemental Table 1. All PCR reactions were done
in triplicate. The comparative Ct method was used to quantify
585 transcripts that were normalized for human GAPDH. The
following set of primers were used: GAPDH FSG 5ʹ-
ACATCATCCCTGCCTCTACTG-3ʹ and RSG 5ʹ-ACCAC
CTGGTGCTCAGTGTA-3ʹ; TREM-1 FSG 5ʹ-TGATCTA
CCAGCCTCCCAAG-3ʹ and RSG 5ʹ-AGCTTGGGTC
590 ACAGTTCTGG-3ʹ; ABCA1 FSG 5ʹ-CCAGGCCAGTA
CGGAATTC-3ʹ and RSG 5ʹ-CCTCGCCAAACCAGTAGGA-
3ʹ; TGM2 FSG 5ʹ-GCCACTTCATTTTGCTCTTCAA-3ʹ and
RSG 5ʹ-TCCTCTTCCGAGTCCAGGTACA-3ʹ.
Mixed lymphocytes reaction and intracellular staining
595 DCs (1 x 104) activated with LPS (100 ng/ml) in the presence
or absence of 9-Cis Retinoic Acid (1 μM) and activated with
were co-cultured with allogenic CD4+ Naïve T cells (1 x 105
cells/well) isolated with the naive CD4+ T Cell Isolation Kit II
(Miltenyi Biotec). After 72 hours rhIL-2 (10 U/ml) was added.
600 On days 6 each MLR was stained with an anti-CD3 antibody
and analyzed by flow cytometry intracellular staining for the
cytokines TNFα and IFNγ.
Mixed lymphocytes reaction and T cell proliferation
Monocyte-DCs (1.5 x 105) were activated with LPS (100 ng/
605 ml) in the presence of 9-Cis Retinoic Acid (1 μM) and stimu-
lated with anti-TREM-1 mAb or with control IgG1 for
24 hours. Then, DCs were collected, washed and co-cultured
(1 x 104) with allogenic T cells (1 x 105 cells/well) previously
isolated with the Pan T cell isolation kit (Miltenyi) and labeled
610 with 5 μM of CFSE for 20ʹ. After 72 hours rhIL-2 (10 U/ml)
was added. On day 6 each MLR was analyzed by FACS. The
T cell proliferation was calculated as the percentage of CFSE+
T cells as compared to non-stimulated CFSE+ T cells.
Chemotaxis assay
615 Chemotaxis assays were performed using 5-μm pore polycar-
bonate filters in a 24-well transwell chamber (Corning Costar
Corporation). Human T lymphocytes from peripheral blood
mononuclear cells of healthy donors were isolated by using
the Pan T cell isolation kit (Miltenyi). Purified T cells (2 x 105/
620 100 μl) in RPMI 0.5% BSA were seeded in the upper chamber,
whereas in the lower chamber we added 600 μl of medium
(RPMI 10% Hyclone) or 600 μl of supernatants from DCs
activated for 24 hours with LPS in the presence of 9-Cis
Retinoic Acid and stimulated with either anti-TREM-1 mAb
625or control IgG. Two hours later, migrated cells were measured
by flow cytometer acquisition of a fixed number of beads
(5.000/sample) (Polysciences). Results of migration experi-
ments were calculated as described previously.48
Spontaneous migration was always subtracted.
630Chromatin immunoprecipitacion assay
ChIP experiments were performed using the U937 line differ-
entiated with PMA 10 ng/ml for 72 h and subsequently
stimulated with T1317 or AtRA for 6 hours. In brief,
20 × 106 cells were fixed for 10 min at RT with 1% formalde-
635hyde. Crosslinking was terminated by the addition of 125 mM
glycine. Cells were rinsed with PBS and centrifuged at
1500 rpm for 5 min at 4°C. Pellets were resuspended in
50 nM Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA,
10% glycerol, 0.5% NP-40, 0.25% Triton X-100 and leupeptin-
640pepstatinA-aprotinin at 5 μg/ml [pH 8.1]. Nuclei were col-
lected by centrifugation (4500 rpm for 5 min at 4°C), resus-
pended in 10 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA,
0.5 mM EGTA and leupeptin-pepstatinA-aprotinin at 5 μg/ml
[pH 8.1], and rotated for 10 min at 4°C. Washed nuclei were
645centrifuged, resuspended in 1 mM EDTA, 10 mM Tris-HCl,
100 mM NaCl, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5%
N-sauroylsarconsin and leupeptin-pepstatinA-aprotinin at
5 μg/ml [pH 8.1], and then sonicated to generate DNA frag-
ment sizes of 0.2–0.8 kb, using the Diagenode Bioruptor twin
650(20 cycles, 30 s on/off, maximum power). Samples were
cleared by centrifugation at 14000 rpm for 10 min at 4°C.
2.5 % of the cleared supernatant was used as input, and the
remaining volume was immunoprecipitated with 4 μg of anti-
LXR antibody (provided by Knut R. Steffensen),49,50 or anti-
655RAR (sc-773 Santa Cruz)22 and a rabbit IgG serum.
Immunoprecipitated DNA was purified using Qiaquick PCR
Purification kit (Qiagen), and amplified by qPCR on a ViiA7,
Applied Biosystems. Regions within TREM-1 promoter were
tested using the following primers: Vimentin FSG 5ʹ-
660CCATGGTTACACCAC-3ʹ and RSG 5ʹ-AGTA
AGAGCGTGCTG-3ʹ; SREBP-1c FSG 5ʹ-AGCGGGTTA
AAGGCGGAC-3ʹ and RSG 5ʹ-AGTTTCACCCCGCGGC-3ʹ;
ALDH1A1 FSG 5ʹ-GGCCTTAGTGGCCAGAGCAG-3ʹ and
RSG 5ʹ-TGCACGGGCTAAAGTTTATTTGC-3ʹ; TREM-1B
665FSG 5ʹ-TGGGCCTGACTCTCTTCACT-3ʹ and RSG 5ʹ-
TGACCTAGAGGCTTCGGAAA-3ʹ. We identified two puta-
tive LXRE in the 5ʹ-untranslated regions of the TREM-1
promoter (one at −197/-221 and the other one at −285/-309
bp). The primers used to amplify the immunoprecipitated
670DNA encompass both the LXRE sequences (between the
−346 bp 5ʹ -untranslated region and +1 bp). We used
TREM-1 primers as reported in.49
Analysis of TREM-1+ DCs in healthy donors and fluids
from cancer patients
675Cells from blood of 9 healthy donors were separated by Ficoll
gradient, washed twice with PBS and then stained with the
following mAbs anti-human CD11b-PerCP-Cy5.5, CD16-
FITC, CD11c-PE, CD1c-PE-Cy7, TREM-1-APC, HLA-DR-
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APC-Cy7. Dead cells were excluded by Dead Cell Stain Kit
680 (Live/Dead Fixable Pacific Blue) used accordingly to the man-
ufacturer’s recommendations. CD11b+ cells were purified
from fluids of 9 advanced cancer patients and stained with
the above-reported mAbs. CD11b+ cells were isolated with
CD11b MicroBeads (Miltenyi Biotec). Samples were run on
685 a Canto II flow cytometer (BD) and analyzed by FlowJo soft-
ware, gating on live cells. Whisker plot analysis of the results
between the two groups was performed by Wilcoxon
matched-pairs signed rank test with Prism software.
Peripheral blood mononuclear cells from healthy donors and
690 fluids from cancer patients were obtained after written
informed consent approved by the Institutional Ethics
Committee
TREM-1, ABCA1 and TGM2 expression and statistical
association among the transcripts
695 Monocyte-DCs were activated with LPS and exposed to
pleural effusions for 24 h. Then, mono-DCs were collected
and RNA extracted by TRIZOL as described above. Samples
were then analyzed by qPCR for the expression of TREM-1,
ABCA1 and TGM-2 transcripts. A written informed consent
700 was appropriately signed by cancer patients before using
pleural effusions or ascites. To show the correlation between
ABCA1 and TREM-1 and between TGM2 and TREM-1,
a X-Y graph was built up using the numerical values and
the trend lines obtained after a simple linear regression ana-
705 lysis. By using the same method, the coefficients of determi-
nation, R2, and the p-values were obtained and reported in
the text. No logarithmic transformation of the numerical
values was performed and outliers where removed whenever
applicable. In the reported graphs both ABCA1 and TGM2
710 were treated as independent variables whereas TREM-1 as
a dependent variable.
Analysis of TREM-1 and ITGAX expression and overall
survival and relapse free survival in NSCLC and ovarian
cancer sample datasets
715 The correlation between TREM1, or TREM1 plus ITGAX
(CD11c) gene expression and Overall Survival or Relapse
Free Survival in NSCLC and Ovarian Cancer was performed
by using the PROGgeneV2 Prognostic Database.24 For
NSCLC samples the analysis was performed by interrogating
720 the GSE8894 datasets containing 137 postoperative NSCLC
samples (69 High expressors and 68 Low expressors). For
ovarian cancer samples the analysis was performed by inter-
rogating the TCGA datasets containing 578 ovarian samples
(289 High expressors and 289 Low expressors). For creation
725 of Kaplan Meier plots, gene expression variable (High and
Low expressors) was bifurcated based on median.
Tumor challenge in wild-type and Trem1,3-/- chimera
mice
We transplanted lethally irradiated (11 Gy) C57BL/6 mice
730 with bone marrow of Trem1,3−/-, or wild type mice (5 × 106
bone marrow cells/mouse). Six-eight weeks later, we
challenged mice with LLC tumor cells (0.35 x 106). TREM-1
analysis was performed by FACS on splenocytes at the end of
the experiments. Transplanted mice were treated with enro-
735floxacin for 15 days (7.5 mg/150 μl Baytril 5% solution in
300 ml of drinking water) accordingly to the indication of the
veterinary staff of our spf facility. We evaluated tumor size by
measuring perpendicular diameters by a caliper. Data are
reported as the mean tumor volume ± SEM. Animal studies
740were approved by the Institutional Animal Care and Use
Committee of the San Raffaele Scientific Institute (IACUC n
° 656) and by the Italian Ministry of Health.
Analysis of LLC-infiltrating cells
Tumors collected 17 days after injection were cut into small
745fragments and digested for 45–60 min at 37°C with 1.4 mg/ml
collagenase A, B, and D (Roche) and 40 μg/ml DNase
(Roche) mixture in RPMI medium with 10% FBS. Single
cell suspensions were washed and labeled with Dead Cell Stain
kit reagents for 30 min at 4°C. After washing, the cells were
750incubated for 5 min at RT with Fc-blocking solution (10 μg/
ml mouse Fc Block; BD) and labeled with CD11b, Ly6G,
CD11c CD45.1, or CD45.2 mAbs (Biolegend) and anti-
mouse TREM-1 (R&D Systems). Samples were run by
FACSCalibur flow cytometer (BD) and analyzed by FlowJo
755software gating on live cells.
Immunohistochemistry and quantification of
tumor-infiltrating CD3+ and CD8+ cells
Deparaffinated histologic sections after antigen retrieval were
incubated for 1 h at RT with primary anti-CD3 (clone CD2-
76012, BioRad) or anti-CD8 antibodies (clone D4W27
Cellsignal), followed, after rinsing in PBS, by rat on mouse
HRP polymer (RT517 Biocare) or rabbit on rodent HRP
polymer (RMR622 Biocare) respectively, and developed with
DAB and H2O2. The amount of immunoreactive CD3
+ and
765CD8+ cells was calculated as the number of positive cells in
tumor areas at 400x magnification in 16 high-power fields
enriched of T lymphocytes. The analysis was performed on
slides from 2 experiments with 3 mice/group (Wild type vs
Trem-1,3−/- bone marrow chimera mice challenged with LLC
770tumors as described above).
Statistical analysis
Data are expressed as mean ± SEM and were analyzed for
significance by ANOVA with Dunnet’s, Bonferroni’s or
Tukey’s multiple comparison test, or by Student’s t test. The
775analysis was performed with Prism software.
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